In clinical settings, it was also found that high KIFC2 mRNA expression was associated with tumor growth and poor survival of patients with HR+/HER2– BC who received ET alone or in combination with CDK4/6 inhibitors (Figure 7). Here, ERBB2 is linked to breast cancer.